What are the potential side effects of prolonged cosentyx use?

What side effects show up after long-term Cosentyx use?

Cosentyx (secukinumab) blocks IL-17 and reduces inflammation in psoriasis, psoriatic arthritis, and ankylosing spondylitis. Long-term safety data come mainly from extension studies that track patients over five years or more. Those reports list infections as the most common issue, especially upper respiratory tract infections that keep recurring.

How do infections develop during extended treatment?

IL-17 plays a role in defending against bacteria and fungi at mucosal surfaces. Blocking it leaves some patients susceptible to candida infections, both oral and genital. Upper respiratory infections occur in roughly 10-15% of patients, but they are usually mild and do not force treatment stoppage.

Are serious infections a real risk?

Rare cases of serious bacterial infections and tuberculosis reactivation have been reported. Patients who test positive for latent TB must complete treatment before starting Cosentyx. Ongoing monitoring for signs of infection remains standard practice.

Why do some patients develop inflammatory bowel disease?

New-onset or worsening Crohn’s disease and ulcerative colitis have been observed in a few patients. Because IL-17 is protective in the gut, its blockage can unmask latent inflammatory bowel disease. Doctors screen for gut symptoms at every visit.

Can Cosentyx affect liver enzymes or cause other lab changes?

Transient rises in liver enzymes occur, but they usually keep themselves within normal limits. Neutropenia appears occasionally, but counts recover once the dose is lowered or treatment stops.

What happens to injection-site reactions over time?

Mild erythema or pain at the injection site happens in 2-3% of patients. Reactions tend to abate as the body adapts to repeated injections.

When does patent protection end for Cosentyx?

Cosentyx faces patent expiration around 2030. Biosimilars may arrive earlier in some markets once regulatory pathways open.